Drug studies · CTIS · 4 minutes reading

Clinical trials digest

Drug trials: ICH, CTIS, SUSAR, and the eCTD file

Medicinal-product trials in Europe run under CTR 536/2014 and CTIS. In the United States they run under IND and FDA review. Both need CDISC tabulations, safety cases, and a protocol the statistician can lock.

Drug trialsCTISICHPharmacovigilance
← All articles

4 min

Reading time

EU+US

Doctors and sites

1 record

Drug, device, IVD

One medicinal-product trial, two authority doors

A drug study is still a protocol, sites, and participants. The paperwork around it is not. In the European Union, CTR 536/2014 and the Clinical Trials Information System (CTIS) are the door. In the United States, the IND and FDA review are the door. ICH guidelines — E6 for GCP, E2A and E2B for safety, M11 for the protocol, E8 for general considerations — try to keep the science aligned. Sponsors who capture the study twice to feed both doors invent discrepancies. ValidTrials holds the capture once. We assemble the packages the door requires. The investigator still sees a visit, not a submission portal.

One medicinal-product trial, two authority doors

Full article for doctors, investigators, and readers who follow clinical trials.

The protocol as a structured object

ICH M11 and CDISC USDM treat the protocol as data: objectives, endpoints, population, schedule, investigational product. When that structure exists, the EDC, the safety clocks, and the analysis plan can be generated from the same source instead of being typed three times. A protocol amendment then has a version, a reason, and a list of what changed in the visits. Sites are retrained against that version. This is ordinary quality. It is still often a Word file and a hope. Readers in clinical science and regulatory affairs get the operational version in this digest: what must be structured if CTIS and eCTD are not going to be a surprise at the end.

SUSAR clocks and E2B(R3)

Serious unexpected suspected adverse reactions have clocks. The clock starts from awareness, not from when someone found time to open the safety mailbox. E2B(R3) is the message the authority expects. MedDRA coding, seriousness, expectedness, and causality have to be attributable to a person. One case may go to more than one authority. ValidTrials is built so the case and the participant visit are the same record, not an export into a separate safety database that then forgets the query on the CRF. Pharmacovigilance readers subscribe for the clock language, not for a claim about a product’s benefit.

SUSAR clocks and E2B(R3)

Full article for doctors, investigators, and readers who follow clinical trials.

SDTM, ADaM, and Define-XML

When the study is locked, the tabulations (SDTM), the analysis datasets (ADaM), and the define file are how a statistician and an assessor read the evidence. If those datasets are handmade from spreadsheets, the method cannot be named cleanly. If they come from the same system that captured the visit, the trace from a number on a form to a number in a table is an audit trail instead of a legend. ValidTrials is designed for that trace. Today it produces SDTM- and ADaM-shaped extracts for review, not certified submission datasets. The statistical method and the software versions are stored. A person still signs the conclusion. The software does not write that the product is clinically validated.

What drug teams should ask a CRO

Ask who configures the schedule of activities from the protocol. Ask where SUSARs live relative to the CRF. Ask whether SDTM is a mapping from the capture or a second typing. Ask how an EU and a US package stay the same study. We answer those questions with the record, not with a slide. The newsletter will keep those questions in circulation for medical monitors, clinical scientists, and regulatory leads who are tired of reconciling five vendors at database lock.

What drug teams should ask a CRO

Full article for doctors, investigators, and readers who follow clinical trials.

Read more from the digest.

Subscribe, or bring us the protocol.

The digest is for doctors and trial readers. The study conversation starts with us.